Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | CYP11B1 | P15538 | 9/20 | 0.63 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.63 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.63 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78081 | 0.95 | CYP19A1 (1.00) | CYP19A1KMT2ACYP11B1CYP11B2CYP2A6 | |
| SCHEMBL2529997 | 0.84 | CYP11B1 (0.86) | CYP19A1CYP11B1CYP11B2CYP17A1CYP2A6 | |
| SCHEMBL1838287 | 0.83 | CYP19A1 (0.66) | CYP19A1KMT2ACYP11B1CYP11B2CYP17A1 | |
| SCHEMBL9663626 | 0.81 | CYP19A1 (1.00) | CYP19A1KMT2ACYP11B1CYP11B2 | |
| SCHEMBL28140208 | 0.80 | CYP19A1 (0.72) | CYP19A1KMT2ACYP11B1CYP11B2ALDH1A1 | |
| SCHEMBL6868756 | 0.80 | CYP11B1 (0.68) | CYP19A1KMT2ACYP11B1CYP11B2CYP17A1 | |
| Hydrochloric Acid SCHEMBL9663915 | 0.79 | CYP19A1 (0.97) | CYP19A1KMT2ACYP11B1CYP11B2 | |
| SCHEMBL31415763 | 0.79 | CYP19A1 (0.70) | CYP19A1KMT2ACYP11B1CYP11B2 | |
| SCHEMBL31415762 | 0.79 | CYP19A1 (0.70) | CYP19A1KMT2ACYP11B1CYP11B2 | |
| SCHEMBL27632062 | 0.79 | CYP19A1 (0.69) | CYP19A1KMT2ACYP11B1CYP11B2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | MAPK3, MAPK1, MAPKAPK3 | CYP19A1 991/4885KMT2A 2259/4885CYP11B1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.